Safety and efficacy of continuous intravenous labetalol for blood pressure control in neurosurgery

Completed

• Conditions: eurosurgical patients complicated with hypertension during perioperative period; continuous intravenous; labetalol; hypertension; neurosurgery; bradycardia; hypotension

• Registration Number: TCTR20221227005
• Lead Sponsor: /A

Brief Summary

The efficacy and safety profiles of labetalol infusion suggest that this treatment is a promising option for controlling BP in neurosurgical patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-27
• Study Completion: 2022-12-30
• Results First Posted: 2023-11-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Neurosurgical patients complicated with hypertension who received continuous intravenouslabetalol administration from November 1, 2021 to October 31, 2022

Exclusion Criteria

1. pregnancy
2. patients who received other antihypertensive agents with labetalol
3. brain death
4. patients who received other drugs that affected to hemodynamics
5. patients who were ongoing triple H therapy during subarachnoid hemorrhage
6. patients with neurosurgical that were not related to brain, such as spinal disorders or peripheral nerve diseases

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to achieve blood pressure control time from drug initiation to target blood pressure hour,adverse event Time from drug initiation until termination number of patients with adverse events

Secondary Outcome Measures

Name	Time	Method
cumulative dose at adverse event Time from drug initiation until event occur milligram,cumulative dose at blood pressure target Time from drug initiation until achievement milligram,factors associating with adverse events Time from drug initiation until event occur association between factor and adverse event